Platinum Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
Other funds holding BMRN
BBA
Platinum Investment Management's BMRN Position: Q3 2019 in Review
Platinum Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 13,820 shares — an estimated $1.18M sold.
Platinum Investment Management first reported a position in BMRN in Q2 2013 and held it in 25 quarters. The position peaked at $3.03M in Q4 2014. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.
- Platinum Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
- Platinum Investment Management sold 13,820 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $1.18M.
- Platinum Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 25 quarters.
- Platinum Investment Management's BioMarin Pharmaceuticals position peaked at $3.03M in Q4 2014.
- 437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.
Based on Platinum Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.